nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—prostate cancer	0.239	1	CbGaD
Solifenacin—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0774	0.207	CbGbCtD
Solifenacin—CYP3A4—Bicalutamide—prostate cancer	0.0407	0.109	CbGbCtD
Solifenacin—CYP3A4—Estramustine—prostate cancer	0.0378	0.101	CbGbCtD
Solifenacin—CYP3A4—Abiraterone—prostate cancer	0.0337	0.09	CbGbCtD
Solifenacin—CYP3A4—Flutamide—prostate cancer	0.0337	0.09	CbGbCtD
Solifenacin—CYP3A4—Cabazitaxel—prostate cancer	0.0249	0.0666	CbGbCtD
Solifenacin—CYP3A4—Estrone—prostate cancer	0.0244	0.0651	CbGbCtD
Solifenacin—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0217	0.058	CbGbCtD
Solifenacin—CYP3A4—Conjugated Estrogens—prostate cancer	0.0159	0.0426	CbGbCtD
Solifenacin—CHRM3—ureter—prostate cancer	0.0159	0.478	CbGeAlD
Solifenacin—CYP3A4—Mitoxantrone—prostate cancer	0.0145	0.0387	CbGbCtD
Solifenacin—CYP3A4—Estradiol—prostate cancer	0.014	0.0374	CbGbCtD
Solifenacin—CYP3A4—Prednisone—prostate cancer	0.012	0.0321	CbGbCtD
Solifenacin—CYP3A4—Etoposide—prostate cancer	0.00913	0.0244	CbGbCtD
Solifenacin—CYP3A4—Docetaxel—prostate cancer	0.00836	0.0223	CbGbCtD
Solifenacin—CYP3A4—Doxorubicin—prostate cancer	0.00623	0.0166	CbGbCtD
Solifenacin—CYP3A4—urine—prostate cancer	0.00284	0.0854	CbGeAlD
Solifenacin—CHRM5—epithelium—prostate cancer	0.00244	0.0733	CbGeAlD
Solifenacin—CHRM2—prostate gland—prostate cancer	0.00228	0.0685	CbGeAlD
Solifenacin—CHRM1—prostate gland—prostate cancer	0.00207	0.0623	CbGeAlD
Solifenacin—CHRM4—testis—prostate cancer	0.00187	0.0562	CbGeAlD
Solifenacin—CHRM3—prostate gland—prostate cancer	0.00185	0.0558	CbGeAlD
Solifenacin—Benazepril—MTHFR—prostate cancer	0.00134	0.473	CrCbGaD
Solifenacin—CHRM3—renal system—prostate cancer	0.00126	0.038	CbGeAlD
Solifenacin—CHRM3—urethra—prostate cancer	0.00124	0.0373	CbGeAlD
Solifenacin—Benazepril—ACE—prostate cancer	0.00109	0.386	CrCbGaD
Solifenacin—CHRM3—testis—prostate cancer	0.000816	0.0246	CbGeAlD
Solifenacin—CYP3A4—renal system—prostate cancer	0.000694	0.0209	CbGeAlD
Solifenacin—Mequitazine—CYP3A4—prostate cancer	0.000399	0.141	CrCbGaD
Solifenacin—Headache—Conjugated Estrogens—prostate cancer	0.000153	0.000586	CcSEcCtD
Solifenacin—Confusional state—Etoposide—prostate cancer	0.000153	0.000585	CcSEcCtD
Solifenacin—Muscular weakness—Epirubicin—prostate cancer	0.000152	0.000584	CcSEcCtD
Solifenacin—Hallucination—Prednisone—prostate cancer	0.000152	0.000583	CcSEcCtD
Solifenacin—Anaphylactic shock—Etoposide—prostate cancer	0.000151	0.000581	CcSEcCtD
Solifenacin—Dysgeusia—Docetaxel—prostate cancer	0.000151	0.000579	CcSEcCtD
Solifenacin—Infection—Etoposide—prostate cancer	0.00015	0.000577	CcSEcCtD
Solifenacin—Mental disorder—Capecitabine—prostate cancer	0.00015	0.000576	CcSEcCtD
Solifenacin—Connective tissue disorder—Prednisone—prostate cancer	0.00015	0.000576	CcSEcCtD
Solifenacin—Feeling abnormal—Mitoxantrone—prostate cancer	0.00015	0.000575	CcSEcCtD
Solifenacin—Malnutrition—Capecitabine—prostate cancer	0.000149	0.000572	CcSEcCtD
Solifenacin—Influenza—Epirubicin—prostate cancer	0.000149	0.000572	CcSEcCtD
Solifenacin—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000149	0.000571	CcSEcCtD
Solifenacin—Tachycardia—Etoposide—prostate cancer	0.000148	0.000567	CcSEcCtD
Solifenacin—Liver function test abnormal—Doxorubicin—prostate cancer	0.000147	0.000566	CcSEcCtD
Solifenacin—Skin disorder—Etoposide—prostate cancer	0.000147	0.000564	CcSEcCtD
Solifenacin—Dry skin—Doxorubicin—prostate cancer	0.000146	0.000562	CcSEcCtD
Solifenacin—Nausea—Goserelin—prostate cancer	0.000146	0.000561	CcSEcCtD
Solifenacin—Dysgeusia—Capecitabine—prostate cancer	0.000146	0.000561	CcSEcCtD
Solifenacin—Abdominal pain upper—Doxorubicin—prostate cancer	0.000146	0.00056	CcSEcCtD
Solifenacin—Nausea—Conjugated Estrogens—prostate cancer	0.000145	0.000556	CcSEcCtD
Solifenacin—Urticaria—Mitoxantrone—prostate cancer	0.000145	0.000555	CcSEcCtD
Solifenacin—Hypersensitivity—Estradiol—prostate cancer	0.000144	0.000552	CcSEcCtD
Solifenacin—Abdominal pain—Mitoxantrone—prostate cancer	0.000144	0.000552	CcSEcCtD
Solifenacin—Eye disorder—Prednisone—prostate cancer	0.000143	0.000547	CcSEcCtD
Solifenacin—Muscular weakness—Doxorubicin—prostate cancer	0.000141	0.00054	CcSEcCtD
Solifenacin—Vision blurred—Capecitabine—prostate cancer	0.000141	0.000539	CcSEcCtD
Solifenacin—Asthenia—Estradiol—prostate cancer	0.00014	0.000537	CcSEcCtD
Solifenacin—Dysuria—Epirubicin—prostate cancer	0.00014	0.000535	CcSEcCtD
Solifenacin—Angiopathy—Prednisone—prostate cancer	0.000139	0.000531	CcSEcCtD
Solifenacin—Pruritus—Estradiol—prostate cancer	0.000138	0.00053	CcSEcCtD
Solifenacin—Influenza—Doxorubicin—prostate cancer	0.000138	0.00053	CcSEcCtD
Solifenacin—Immune system disorder—Prednisone—prostate cancer	0.000138	0.000529	CcSEcCtD
Solifenacin—Palpitations—Docetaxel—prostate cancer	0.000136	0.000522	CcSEcCtD
Solifenacin—Somnolence—Etoposide—prostate cancer	0.000135	0.000516	CcSEcCtD
Solifenacin—Cough—Docetaxel—prostate cancer	0.000134	0.000516	CcSEcCtD
Solifenacin—Hypersensitivity—Mitoxantrone—prostate cancer	0.000134	0.000514	CcSEcCtD
Solifenacin—Mental disorder—Prednisone—prostate cancer	0.000134	0.000513	CcSEcCtD
Solifenacin—Hypertension—Docetaxel—prostate cancer	0.000133	0.00051	CcSEcCtD
Solifenacin—Infestation—Epirubicin—prostate cancer	0.000133	0.00051	CcSEcCtD
Solifenacin—Infestation NOS—Epirubicin—prostate cancer	0.000133	0.00051	CcSEcCtD
Solifenacin—Malnutrition—Prednisone—prostate cancer	0.000133	0.00051	CcSEcCtD
Solifenacin—Palpitations—Capecitabine—prostate cancer	0.000132	0.000506	CcSEcCtD
Solifenacin—Decreased appetite—Etoposide—prostate cancer	0.000132	0.000505	CcSEcCtD
Solifenacin—Renal failure—Epirubicin—prostate cancer	0.000131	0.000502	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Etoposide—prostate cancer	0.000131	0.000501	CcSEcCtD
Solifenacin—Asthenia—Mitoxantrone—prostate cancer	0.000131	0.000501	CcSEcCtD
Solifenacin—Fatigue—Etoposide—prostate cancer	0.00013	0.000501	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.00013	0.0005	CcSEcCtD
Solifenacin—Cough—Capecitabine—prostate cancer	0.00013	0.0005	CcSEcCtD
Solifenacin—Constipation—Etoposide—prostate cancer	0.000129	0.000497	CcSEcCtD
Solifenacin—Urinary tract infection—Epirubicin—prostate cancer	0.000129	0.000496	CcSEcCtD
Solifenacin—Dizziness—Estradiol—prostate cancer	0.000129	0.000495	CcSEcCtD
Solifenacin—Dysuria—Doxorubicin—prostate cancer	0.000129	0.000495	CcSEcCtD
Solifenacin—Hypertension—Capecitabine—prostate cancer	0.000129	0.000494	CcSEcCtD
Solifenacin—Dry mouth—Docetaxel—prostate cancer	0.000128	0.000492	CcSEcCtD
Solifenacin—Confusional state—Docetaxel—prostate cancer	0.000127	0.000487	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000126	0.000484	CcSEcCtD
Solifenacin—Hepatobiliary disease—Epirubicin—prostate cancer	0.000126	0.000483	CcSEcCtD
Solifenacin—Anaphylactic shock—Docetaxel—prostate cancer	0.000126	0.000483	CcSEcCtD
Solifenacin—Vision blurred—Prednisone—prostate cancer	0.000125	0.000481	CcSEcCtD
Solifenacin—Infection—Docetaxel—prostate cancer	0.000125	0.000479	CcSEcCtD
Solifenacin—Feeling abnormal—Etoposide—prostate cancer	0.000125	0.000478	CcSEcCtD
Solifenacin—Dry mouth—Capecitabine—prostate cancer	0.000124	0.000477	CcSEcCtD
Solifenacin—Vomiting—Estradiol—prostate cancer	0.000124	0.000476	CcSEcCtD
Solifenacin—Gastrointestinal pain—Etoposide—prostate cancer	0.000124	0.000475	CcSEcCtD
Solifenacin—Nervous system disorder—Docetaxel—prostate cancer	0.000123	0.000473	CcSEcCtD
Solifenacin—Rash—Estradiol—prostate cancer	0.000123	0.000472	CcSEcCtD
Solifenacin—Infestation—Doxorubicin—prostate cancer	0.000123	0.000472	CcSEcCtD
Solifenacin—Infestation NOS—Doxorubicin—prostate cancer	0.000123	0.000472	CcSEcCtD
Solifenacin—Dermatitis—Estradiol—prostate cancer	0.000123	0.000472	CcSEcCtD
Solifenacin—Confusional state—Capecitabine—prostate cancer	0.000123	0.000471	CcSEcCtD
Solifenacin—Tachycardia—Docetaxel—prostate cancer	0.000123	0.000471	CcSEcCtD
Solifenacin—Headache—Estradiol—prostate cancer	0.000122	0.000469	CcSEcCtD
Solifenacin—Skin disorder—Docetaxel—prostate cancer	0.000122	0.000469	CcSEcCtD
Solifenacin—Angioedema—Prednisone—prostate cancer	0.000121	0.000466	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—prostate cancer	0.000121	0.000464	CcSEcCtD
Solifenacin—Infection—Capecitabine—prostate cancer	0.000121	0.000464	CcSEcCtD
Solifenacin—Urticaria—Etoposide—prostate cancer	0.00012	0.000461	CcSEcCtD
Solifenacin—Abdominal pain—Etoposide—prostate cancer	0.00012	0.000459	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—prostate cancer	0.00012	0.000459	CcSEcCtD
Solifenacin—Nervous system disorder—Capecitabine—prostate cancer	0.000119	0.000458	CcSEcCtD
Solifenacin—Tachycardia—Capecitabine—prostate cancer	0.000119	0.000456	CcSEcCtD
Solifenacin—Pharyngitis—Epirubicin—prostate cancer	0.000119	0.000455	CcSEcCtD
Solifenacin—Skin disorder—Capecitabine—prostate cancer	0.000118	0.000454	CcSEcCtD
Solifenacin—Urinary tract disorder—Epirubicin—prostate cancer	0.000118	0.000452	CcSEcCtD
Solifenacin—Oedema peripheral—Epirubicin—prostate cancer	0.000118	0.000451	CcSEcCtD
Solifenacin—Connective tissue disorder—Epirubicin—prostate cancer	0.000117	0.00045	CcSEcCtD
Solifenacin—Urethral disorder—Epirubicin—prostate cancer	0.000117	0.000449	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000116	0.000447	CcSEcCtD
Solifenacin—Nausea—Estradiol—prostate cancer	0.000116	0.000445	CcSEcCtD
Solifenacin—Vomiting—Mitoxantrone—prostate cancer	0.000116	0.000444	CcSEcCtD
Solifenacin—Hypertension—Prednisone—prostate cancer	0.000115	0.00044	CcSEcCtD
Solifenacin—Rash—Mitoxantrone—prostate cancer	0.000115	0.00044	CcSEcCtD
Solifenacin—Dermatitis—Mitoxantrone—prostate cancer	0.000115	0.00044	CcSEcCtD
Solifenacin—Headache—Mitoxantrone—prostate cancer	0.000114	0.000437	CcSEcCtD
Solifenacin—Erythema multiforme—Epirubicin—prostate cancer	0.000113	0.000433	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000112	0.000431	CcSEcCtD
Solifenacin—Somnolence—Docetaxel—prostate cancer	0.000112	0.000429	CcSEcCtD
Solifenacin—Eye disorder—Epirubicin—prostate cancer	0.000112	0.000428	CcSEcCtD
Solifenacin—Hypersensitivity—Etoposide—prostate cancer	0.000112	0.000428	CcSEcCtD
Solifenacin—Cardiac disorder—Epirubicin—prostate cancer	0.000111	0.000425	CcSEcCtD
Solifenacin—Dyspepsia—Docetaxel—prostate cancer	0.000111	0.000425	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—prostate cancer	0.00011	0.000421	CcSEcCtD
Solifenacin—Decreased appetite—Docetaxel—prostate cancer	0.000109	0.000419	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—prostate cancer	0.000109	0.000419	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—prostate cancer	0.000109	0.000418	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000109	0.000417	CcSEcCtD
Solifenacin—Asthenia—Etoposide—prostate cancer	0.000109	0.000417	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—prostate cancer	0.000109	0.000417	CcSEcCtD
Solifenacin—Anaphylactic shock—Prednisone—prostate cancer	0.000108	0.000416	CcSEcCtD
Solifenacin—Fatigue—Docetaxel—prostate cancer	0.000108	0.000416	CcSEcCtD
Solifenacin—Angiopathy—Epirubicin—prostate cancer	0.000108	0.000416	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—prostate cancer	0.000108	0.000415	CcSEcCtD
Solifenacin—Nausea—Mitoxantrone—prostate cancer	0.000108	0.000415	CcSEcCtD
Solifenacin—Immune system disorder—Epirubicin—prostate cancer	0.000108	0.000414	CcSEcCtD
Solifenacin—Infection—Prednisone—prostate cancer	0.000108	0.000413	CcSEcCtD
Solifenacin—Mediastinal disorder—Epirubicin—prostate cancer	0.000108	0.000413	CcSEcCtD
Solifenacin—Constipation—Docetaxel—prostate cancer	0.000108	0.000413	CcSEcCtD
Solifenacin—Dyspepsia—Capecitabine—prostate cancer	0.000107	0.000411	CcSEcCtD
Solifenacin—Pruritus—Etoposide—prostate cancer	0.000107	0.000411	CcSEcCtD
Solifenacin—Nervous system disorder—Prednisone—prostate cancer	0.000106	0.000408	CcSEcCtD
Solifenacin—Tachycardia—Prednisone—prostate cancer	0.000106	0.000406	CcSEcCtD
Solifenacin—Decreased appetite—Capecitabine—prostate cancer	0.000106	0.000406	CcSEcCtD
Solifenacin—Skin disorder—Prednisone—prostate cancer	0.000105	0.000404	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000105	0.000403	CcSEcCtD
Solifenacin—Fatigue—Capecitabine—prostate cancer	0.000105	0.000403	CcSEcCtD
Solifenacin—Mental disorder—Epirubicin—prostate cancer	0.000105	0.000401	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—prostate cancer	0.000104	0.000401	CcSEcCtD
Solifenacin—Constipation—Capecitabine—prostate cancer	0.000104	0.000399	CcSEcCtD
Solifenacin—Malnutrition—Epirubicin—prostate cancer	0.000104	0.000399	CcSEcCtD
Solifenacin—Feeling abnormal—Docetaxel—prostate cancer	0.000104	0.000398	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—prostate cancer	0.000103	0.000396	CcSEcCtD
Solifenacin—Gastrointestinal pain—Docetaxel—prostate cancer	0.000103	0.000395	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—prostate cancer	0.000103	0.000393	CcSEcCtD
Solifenacin—Dysgeusia—Epirubicin—prostate cancer	0.000102	0.000391	CcSEcCtD
Solifenacin—Feeling abnormal—Capecitabine—prostate cancer	0.0001	0.000385	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—prostate cancer	0.0001	0.000385	CcSEcCtD
Solifenacin—Dizziness—Etoposide—prostate cancer	0.0001	0.000384	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—prostate cancer	9.98e-05	0.000383	CcSEcCtD
Solifenacin—Gastrointestinal pain—Capecitabine—prostate cancer	9.96e-05	0.000382	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—prostate cancer	9.96e-05	0.000382	CcSEcCtD
Solifenacin—Abdominal pain—Docetaxel—prostate cancer	9.94e-05	0.000381	CcSEcCtD
Solifenacin—Vision blurred—Epirubicin—prostate cancer	9.8e-05	0.000376	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—prostate cancer	9.68e-05	0.000371	CcSEcCtD
Solifenacin—Urticaria—Capecitabine—prostate cancer	9.68e-05	0.000371	CcSEcCtD
Solifenacin—Abdominal pain—Capecitabine—prostate cancer	9.63e-05	0.000369	CcSEcCtD
Solifenacin—Vomiting—Etoposide—prostate cancer	9.62e-05	0.000369	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—prostate cancer	9.62e-05	0.000369	CcSEcCtD
Solifenacin—Dyspepsia—Prednisone—prostate cancer	9.55e-05	0.000366	CcSEcCtD
Solifenacin—Rash—Etoposide—prostate cancer	9.54e-05	0.000366	CcSEcCtD
Solifenacin—Dermatitis—Etoposide—prostate cancer	9.53e-05	0.000366	CcSEcCtD
Solifenacin—Headache—Etoposide—prostate cancer	9.48e-05	0.000364	CcSEcCtD
Solifenacin—Decreased appetite—Prednisone—prostate cancer	9.43e-05	0.000362	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—prostate cancer	9.42e-05	0.000361	CcSEcCtD
Solifenacin—Fatigue—Prednisone—prostate cancer	9.35e-05	0.000359	CcSEcCtD
Solifenacin—Constipation—Prednisone—prostate cancer	9.28e-05	0.000356	CcSEcCtD
Solifenacin—Hypersensitivity—Docetaxel—prostate cancer	9.27e-05	0.000356	CcSEcCtD
Solifenacin—Palpitations—Epirubicin—prostate cancer	9.19e-05	0.000352	CcSEcCtD
Solifenacin—Cough—Epirubicin—prostate cancer	9.07e-05	0.000348	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—prostate cancer	9.07e-05	0.000348	CcSEcCtD
Solifenacin—Asthenia—Docetaxel—prostate cancer	9.03e-05	0.000346	CcSEcCtD
Solifenacin—Nausea—Etoposide—prostate cancer	8.99e-05	0.000345	CcSEcCtD
Solifenacin—Hypertension—Epirubicin—prostate cancer	8.98e-05	0.000344	CcSEcCtD
Solifenacin—Hypersensitivity—Capecitabine—prostate cancer	8.97e-05	0.000344	CcSEcCtD
Solifenacin—Feeling abnormal—Prednisone—prostate cancer	8.94e-05	0.000343	CcSEcCtD
Solifenacin—Pruritus—Docetaxel—prostate cancer	8.9e-05	0.000341	CcSEcCtD
Solifenacin—Gastrointestinal pain—Prednisone—prostate cancer	8.87e-05	0.00034	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	8.79e-05	0.000337	CcSEcCtD
Solifenacin—Asthenia—Capecitabine—prostate cancer	8.74e-05	0.000335	CcSEcCtD
Solifenacin—Dry mouth—Epirubicin—prostate cancer	8.66e-05	0.000332	CcSEcCtD
Solifenacin—Urticaria—Prednisone—prostate cancer	8.62e-05	0.000331	CcSEcCtD
Solifenacin—Pruritus—Capecitabine—prostate cancer	8.62e-05	0.000331	CcSEcCtD
Solifenacin—Abdominal pain—Prednisone—prostate cancer	8.58e-05	0.000329	CcSEcCtD
Solifenacin—Confusional state—Epirubicin—prostate cancer	8.56e-05	0.000328	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—prostate cancer	8.5e-05	0.000326	CcSEcCtD
Solifenacin—Anaphylactic shock—Epirubicin—prostate cancer	8.48e-05	0.000325	CcSEcCtD
Solifenacin—Infection—Epirubicin—prostate cancer	8.43e-05	0.000323	CcSEcCtD
Solifenacin—Cough—Doxorubicin—prostate cancer	8.39e-05	0.000322	CcSEcCtD
Solifenacin—Nervous system disorder—Epirubicin—prostate cancer	8.32e-05	0.000319	CcSEcCtD
Solifenacin—Dizziness—Docetaxel—prostate cancer	8.32e-05	0.000319	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—prostate cancer	8.3e-05	0.000319	CcSEcCtD
Solifenacin—Tachycardia—Epirubicin—prostate cancer	8.28e-05	0.000318	CcSEcCtD
Solifenacin—Skin disorder—Epirubicin—prostate cancer	8.24e-05	0.000316	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	8.13e-05	0.000312	CcSEcCtD
Solifenacin—Dizziness—Capecitabine—prostate cancer	8.05e-05	0.000309	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—prostate cancer	8.01e-05	0.000307	CcSEcCtD
Solifenacin—Vomiting—Docetaxel—prostate cancer	8e-05	0.000307	CcSEcCtD
Solifenacin—Hypersensitivity—Prednisone—prostate cancer	7.99e-05	0.000307	CcSEcCtD
Solifenacin—Rash—Docetaxel—prostate cancer	7.93e-05	0.000304	CcSEcCtD
Solifenacin—Dermatitis—Docetaxel—prostate cancer	7.92e-05	0.000304	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—prostate cancer	7.92e-05	0.000304	CcSEcCtD
Solifenacin—Headache—Docetaxel—prostate cancer	7.88e-05	0.000302	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—prostate cancer	7.85e-05	0.000301	CcSEcCtD
Solifenacin—Infection—Doxorubicin—prostate cancer	7.8e-05	0.000299	CcSEcCtD
Solifenacin—Asthenia—Prednisone—prostate cancer	7.78e-05	0.000299	CcSEcCtD
Solifenacin—Vomiting—Capecitabine—prostate cancer	7.74e-05	0.000297	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—prostate cancer	7.7e-05	0.000295	CcSEcCtD
Solifenacin—Rash—Capecitabine—prostate cancer	7.68e-05	0.000295	CcSEcCtD
Solifenacin—Pruritus—Prednisone—prostate cancer	7.68e-05	0.000294	CcSEcCtD
Solifenacin—Dermatitis—Capecitabine—prostate cancer	7.67e-05	0.000294	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—prostate cancer	7.66e-05	0.000294	CcSEcCtD
Solifenacin—Headache—Capecitabine—prostate cancer	7.63e-05	0.000293	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—prostate cancer	7.63e-05	0.000293	CcSEcCtD
Solifenacin—Somnolence—Epirubicin—prostate cancer	7.54e-05	0.000289	CcSEcCtD
Solifenacin—Nausea—Docetaxel—prostate cancer	7.47e-05	0.000287	CcSEcCtD
Solifenacin—Dyspepsia—Epirubicin—prostate cancer	7.47e-05	0.000286	CcSEcCtD
Solifenacin—Decreased appetite—Epirubicin—prostate cancer	7.38e-05	0.000283	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Epirubicin—prostate cancer	7.33e-05	0.000281	CcSEcCtD
Solifenacin—Fatigue—Epirubicin—prostate cancer	7.32e-05	0.000281	CcSEcCtD
Solifenacin—Constipation—Epirubicin—prostate cancer	7.26e-05	0.000278	CcSEcCtD
Solifenacin—Nausea—Capecitabine—prostate cancer	7.23e-05	0.000277	CcSEcCtD
Solifenacin—Dizziness—Prednisone—prostate cancer	7.17e-05	0.000275	CcSEcCtD
Solifenacin—Feeling abnormal—Epirubicin—prostate cancer	6.99e-05	0.000268	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—prostate cancer	6.98e-05	0.000268	CcSEcCtD
Solifenacin—Gastrointestinal pain—Epirubicin—prostate cancer	6.94e-05	0.000266	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—prostate cancer	6.91e-05	0.000265	CcSEcCtD
Solifenacin—Vomiting—Prednisone—prostate cancer	6.9e-05	0.000265	CcSEcCtD
Solifenacin—Rash—Prednisone—prostate cancer	6.84e-05	0.000262	CcSEcCtD
Solifenacin—Dermatitis—Prednisone—prostate cancer	6.83e-05	0.000262	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—prostate cancer	6.82e-05	0.000262	CcSEcCtD
Solifenacin—Headache—Prednisone—prostate cancer	6.8e-05	0.000261	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—prostate cancer	6.78e-05	0.00026	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—prostate cancer	6.77e-05	0.00026	CcSEcCtD
Solifenacin—Urticaria—Epirubicin—prostate cancer	6.74e-05	0.000259	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—prostate cancer	6.71e-05	0.000258	CcSEcCtD
Solifenacin—Abdominal pain—Epirubicin—prostate cancer	6.71e-05	0.000257	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—prostate cancer	6.47e-05	0.000248	CcSEcCtD
Solifenacin—Nausea—Prednisone—prostate cancer	6.44e-05	0.000247	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—prostate cancer	6.42e-05	0.000246	CcSEcCtD
Solifenacin—Hypersensitivity—Epirubicin—prostate cancer	6.25e-05	0.00024	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—prostate cancer	6.24e-05	0.000239	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—prostate cancer	6.21e-05	0.000238	CcSEcCtD
Solifenacin—Asthenia—Epirubicin—prostate cancer	6.09e-05	0.000234	CcSEcCtD
Solifenacin—Pruritus—Epirubicin—prostate cancer	6e-05	0.00023	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—prostate cancer	5.78e-05	0.000222	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—prostate cancer	5.63e-05	0.000216	CcSEcCtD
Solifenacin—Dizziness—Epirubicin—prostate cancer	5.61e-05	0.000215	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—prostate cancer	5.55e-05	0.000213	CcSEcCtD
Solifenacin—Vomiting—Epirubicin—prostate cancer	5.39e-05	0.000207	CcSEcCtD
Solifenacin—Rash—Epirubicin—prostate cancer	5.35e-05	0.000205	CcSEcCtD
Solifenacin—Dermatitis—Epirubicin—prostate cancer	5.34e-05	0.000205	CcSEcCtD
Solifenacin—Headache—Epirubicin—prostate cancer	5.32e-05	0.000204	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—prostate cancer	5.19e-05	0.000199	CcSEcCtD
Solifenacin—Nausea—Epirubicin—prostate cancer	5.04e-05	0.000193	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—prostate cancer	4.99e-05	0.000191	CcSEcCtD
Solifenacin—Rash—Doxorubicin—prostate cancer	4.95e-05	0.00019	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—prostate cancer	4.95e-05	0.00019	CcSEcCtD
Solifenacin—Headache—Doxorubicin—prostate cancer	4.92e-05	0.000189	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—prostate cancer	4.66e-05	0.000179	CcSEcCtD
Solifenacin—CYP3A4—Metabolism—GNG5—prostate cancer	7.17e-06	7.98e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CREBBP—prostate cancer	7.16e-06	7.98e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—LEP—prostate cancer	7.16e-06	7.98e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ERBB2—prostate cancer	7.15e-06	7.96e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CAV1—prostate cancer	7.12e-06	7.93e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CAV1—prostate cancer	7.09e-06	7.9e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LEP—prostate cancer	7.09e-06	7.9e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCL8—prostate cancer	7.08e-06	7.89e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CB—prostate cancer	7.05e-06	7.86e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KDR—prostate cancer	7.04e-06	7.84e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CAV1—prostate cancer	7.03e-06	7.82e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KDR—prostate cancer	7.01e-06	7.81e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KDR—prostate cancer	6.95e-06	7.74e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CDKN1B—prostate cancer	6.91e-06	7.7e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOA3—prostate cancer	6.9e-06	7.69e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ESR1—prostate cancer	6.86e-06	7.64e-05	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AKT1—prostate cancer	6.84e-06	7.62e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ESR1—prostate cancer	6.84e-06	7.61e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CD—prostate cancer	6.79e-06	7.57e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCL8—prostate cancer	6.78e-06	7.55e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CASP3—prostate cancer	6.78e-06	7.55e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ESR1—prostate cancer	6.77e-06	7.54e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL2—prostate cancer	6.77e-06	7.54e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6—prostate cancer	6.73e-06	7.5e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—BAD—prostate cancer	6.69e-06	7.46e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—BAD—prostate cancer	6.67e-06	7.43e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CDKN1B—prostate cancer	6.62e-06	7.37e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—BAD—prostate cancer	6.61e-06	7.36e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCND1—prostate cancer	6.6e-06	7.35e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HPGDS—prostate cancer	6.59e-06	7.34e-05	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AKT1—prostate cancer	6.55e-06	7.29e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.54e-06	7.29e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CTNNB1—prostate cancer	6.53e-06	7.27e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CASP3—prostate cancer	6.49e-06	7.23e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APC—prostate cancer	6.48e-06	7.22e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	6.48e-06	7.22e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL2—prostate cancer	6.48e-06	7.22e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	6.46e-06	7.2e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APC—prostate cancer	6.46e-06	7.2e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—prostate cancer	6.45e-06	7.18e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—NOS3—prostate cancer	6.42e-06	7.15e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGF—prostate cancer	6.41e-06	7.14e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IRS1—prostate cancer	6.41e-06	7.14e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MMP9—prostate cancer	6.4e-06	7.13e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APC—prostate cancer	6.4e-06	7.13e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	6.4e-06	7.13e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTT1—prostate cancer	6.39e-06	7.11e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ACHE—prostate cancer	6.39e-06	7.11e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IRS1—prostate cancer	6.39e-06	7.11e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGF—prostate cancer	6.39e-06	7.11e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CDKN1A—prostate cancer	6.38e-06	7.11e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PTEN—prostate cancer	6.37e-06	7.09e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IRS1—prostate cancer	6.33e-06	7.05e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGF—prostate cancer	6.33e-06	7.05e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCND1—prostate cancer	6.32e-06	7.03e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.31e-06	7.03e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CTNNB1—prostate cancer	6.25e-06	6.97e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—GSK3B—prostate cancer	6.22e-06	6.93e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AKT1—prostate cancer	6.21e-06	6.92e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—GSK3B—prostate cancer	6.2e-06	6.91e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.14e-06	6.84e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—GSK3B—prostate cancer	6.14e-06	6.84e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—INS—prostate cancer	6.14e-06	6.83e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MMP9—prostate cancer	6.13e-06	6.83e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—INS—prostate cancer	6.12e-06	6.81e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CDKN1A—prostate cancer	6.11e-06	6.81e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PRKACB—prostate cancer	6.11e-06	6.8e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PTEN—prostate cancer	6.1e-06	6.79e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EP300—prostate cancer	6.07e-06	6.76e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—INS—prostate cancer	6.06e-06	6.75e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.05e-06	6.73e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CREBBP—prostate cancer	6.01e-06	6.69e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CREBBP—prostate cancer	5.99e-06	6.67e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AKT1—prostate cancer	5.95e-06	6.62e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IGF1—prostate cancer	5.94e-06	6.61e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CREBBP—prostate cancer	5.93e-06	6.61e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CB—prostate cancer	5.92e-06	6.6e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IGF1—prostate cancer	5.92e-06	6.59e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—EGFR—prostate cancer	5.91e-06	6.58e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SRC—prostate cancer	5.9e-06	6.58e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—EGFR—prostate cancer	5.89e-06	6.56e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTGS2—prostate cancer	5.87e-06	6.54e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IGF1—prostate cancer	5.86e-06	6.53e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—EGFR—prostate cancer	5.83e-06	6.49e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EP300—prostate cancer	5.81e-06	6.48e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOA2—prostate cancer	5.76e-06	6.42e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—VEGFA—prostate cancer	5.75e-06	6.4e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	5.74e-06	6.39e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	5.72e-06	6.37e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	5.7e-06	6.35e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—STAT3—prostate cancer	5.69e-06	6.34e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	5.68e-06	6.33e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	5.66e-06	6.31e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SRC—prostate cancer	5.65e-06	6.3e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	5.64e-06	6.29e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	5.64e-06	6.28e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	5.63e-06	6.27e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	5.63e-06	6.27e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	5.62e-06	6.26e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—KRAS—prostate cancer	5.58e-06	6.21e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	5.57e-06	6.21e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	5.56e-06	6.2e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—KRAS—prostate cancer	5.56e-06	6.19e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—KRAS—prostate cancer	5.51e-06	6.13e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—VEGFA—prostate cancer	5.51e-06	6.13e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.5e-06	6.12e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—FGF2—prostate cancer	5.46e-06	6.08e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—STAT3—prostate cancer	5.45e-06	6.07e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—FGF2—prostate cancer	5.44e-06	6.06e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—FGF2—prostate cancer	5.39e-06	6e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOS3—prostate cancer	5.38e-06	5.99e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.37e-06	5.98e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOS3—prostate cancer	5.36e-06	5.97e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOS3—prostate cancer	5.31e-06	5.92e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NQO1—prostate cancer	5.31e-06	5.91e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MYC—prostate cancer	5.29e-06	5.89e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—prostate cancer	5.28e-06	5.88e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TH—prostate cancer	5.23e-06	5.83e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—JAK2—prostate cancer	5.23e-06	5.83e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—JAK2—prostate cancer	5.21e-06	5.81e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EGFR—prostate cancer	5.17e-06	5.76e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—JAK2—prostate cancer	5.16e-06	5.75e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	5.13e-06	5.71e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTEN—prostate cancer	5.12e-06	5.7e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	5.11e-06	5.69e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MDM2—prostate cancer	5.11e-06	5.69e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.09e-06	5.67e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MDM2—prostate cancer	5.09e-06	5.67e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MYC—prostate cancer	5.07e-06	5.64e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	5.06e-06	5.64e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—prostate cancer	5.05e-06	5.63e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MDM2—prostate cancer	5.04e-06	5.61e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ERBB2—prostate cancer	5.03e-06	5.61e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ERBB2—prostate cancer	5.02e-06	5.59e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ERBB2—prostate cancer	4.97e-06	5.53e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	4.97e-06	5.53e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EGFR—prostate cancer	4.96e-06	5.52e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	4.95e-06	5.52e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GGT1—prostate cancer	4.93e-06	5.49e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	4.9e-06	5.46e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—KRAS—prostate cancer	4.89e-06	5.44e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—EP300—prostate cancer	4.88e-06	5.44e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NCOA1—prostate cancer	4.86e-06	5.41e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.78e-06	5.33e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL8—prostate cancer	4.77e-06	5.32e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL8—prostate cancer	4.76e-06	5.3e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL8—prostate cancer	4.71e-06	5.25e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—KRAS—prostate cancer	4.68e-06	5.21e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	4.66e-06	5.19e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	4.65e-06	5.18e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—RXRA—prostate cancer	4.62e-06	5.14e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	4.61e-06	5.14e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	4.6e-06	5.13e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	4.6e-06	5.12e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CASP3—prostate cancer	4.57e-06	5.09e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL2—prostate cancer	4.56e-06	5.08e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CASP3—prostate cancer	4.55e-06	5.07e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	4.55e-06	5.07e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL2—prostate cancer	4.55e-06	5.06e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—prostate cancer	4.54e-06	5.06e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—prostate cancer	4.52e-06	5.04e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CASP3—prostate cancer	4.51e-06	5.02e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL2—prostate cancer	4.5e-06	5.02e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	4.49e-06	5e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—prostate cancer	4.48e-06	4.99e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—COMT—prostate cancer	4.45e-06	4.95e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCND1—prostate cancer	4.45e-06	4.95e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCND1—prostate cancer	4.43e-06	4.94e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTP1—prostate cancer	4.43e-06	4.93e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	4.4e-06	4.91e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCND1—prostate cancer	4.39e-06	4.89e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	4.39e-06	4.89e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ITPR1—prostate cancer	4.36e-06	4.85e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	4.35e-06	4.84e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TP53—prostate cancer	4.34e-06	4.84e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP9—prostate cancer	4.32e-06	4.81e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP9—prostate cancer	4.3e-06	4.79e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	4.3e-06	4.79e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	4.3e-06	4.79e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTEN—prostate cancer	4.29e-06	4.78e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	4.29e-06	4.78e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTEN—prostate cancer	4.28e-06	4.77e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP9—prostate cancer	4.26e-06	4.75e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	4.25e-06	4.73e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTEN—prostate cancer	4.24e-06	4.72e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AKT1—prostate cancer	4.19e-06	4.66e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AKT1—prostate cancer	4.17e-06	4.65e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TP53—prostate cancer	4.16e-06	4.63e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AKT1—prostate cancer	4.13e-06	4.6e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TYMS—prostate cancer	4.12e-06	4.58e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EP300—prostate cancer	4.09e-06	4.56e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EP300—prostate cancer	4.08e-06	4.54e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTM1—prostate cancer	4.07e-06	4.53e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EP300—prostate cancer	4.04e-06	4.5e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—LPL—prostate cancer	3.99e-06	4.45e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SRC—prostate cancer	3.98e-06	4.43e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—prostate cancer	3.98e-06	4.43e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SRC—prostate cancer	3.97e-06	4.42e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SRC—prostate cancer	3.93e-06	4.38e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—VEGFA—prostate cancer	3.88e-06	4.32e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—VEGFA—prostate cancer	3.86e-06	4.3e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.86e-06	4.3e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—STAT3—prostate cancer	3.84e-06	4.28e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—VEGFA—prostate cancer	3.83e-06	4.26e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—STAT3—prostate cancer	3.83e-06	4.26e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ERCC2—prostate cancer	3.83e-06	4.26e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—prostate cancer	3.81e-06	4.24e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—STAT3—prostate cancer	3.79e-06	4.22e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKT1—prostate cancer	3.67e-06	4.09e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3CA—prostate cancer	3.61e-06	4.02e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MTHFR—prostate cancer	3.6e-06	4e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MYC—prostate cancer	3.57e-06	3.97e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—prostate cancer	3.56e-06	3.96e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MYC—prostate cancer	3.56e-06	3.96e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—prostate cancer	3.55e-06	3.95e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPARA—prostate cancer	3.53e-06	3.93e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MYC—prostate cancer	3.52e-06	3.92e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT1—prostate cancer	3.51e-06	3.91e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—prostate cancer	3.51e-06	3.91e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGFR—prostate cancer	3.49e-06	3.89e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGFR—prostate cancer	3.48e-06	3.87e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGFR—prostate cancer	3.44e-06	3.84e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CAV1—prostate cancer	3.32e-06	3.69e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—KRAS—prostate cancer	3.3e-06	3.67e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—KRAS—prostate cancer	3.29e-06	3.66e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—KRAS—prostate cancer	3.25e-06	3.62e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	3.03e-06	3.37e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.02e-06	3.36e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	3.02e-06	3.36e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	2.99e-06	3.33e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AKT1—prostate cancer	2.95e-06	3.28e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TP53—prostate cancer	2.93e-06	3.26e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TP53—prostate cancer	2.92e-06	3.25e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TP53—prostate cancer	2.89e-06	3.22e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—INS—prostate cancer	2.86e-06	3.19e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CREBBP—prostate cancer	2.8e-06	3.12e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—prostate cancer	2.68e-06	2.99e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—prostate cancer	2.67e-06	2.98e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.66e-06	2.96e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—prostate cancer	2.65e-06	2.95e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NOS3—prostate cancer	2.51e-06	2.79e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT1—prostate cancer	2.47e-06	2.76e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT1—prostate cancer	2.47e-06	2.75e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT1—prostate cancer	2.44e-06	2.72e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.31e-06	2.58e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS2—prostate cancer	2.29e-06	2.55e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTEN—prostate cancer	2e-06	2.23e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—EP300—prostate cancer	1.91e-06	2.12e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.41e-06	1.57e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKT1—prostate cancer	1.15e-06	1.28e-05	CbGpPWpGaD
